Latest Industry Insights

In this article, we discuss the role of anti-PLA2R and anti-THSD7A antibodies in the diagnosis of primary membranous nephropathy and highlight why there is a need to measure these biomarkers before kidney transplants.

Dr Stephen Russell explores how measuring neutralizing antibody levels can help understand how risk levels can change over time and determine optimal vaccine dosing strategies.

Testing for the presence of the SARS-CoV-2 virus continues to be critical across the world, and will be in the future, particularly in light of new variants. The key to expanding and perfecting testing lies, arguably, in effective partnerships between organizations.

Technology Networks recently spoke with Jean-François Bellec, ProteinSimple applications scientist, to learn about Bio-Techne’s history and how its solutions enable researchers to work efficiently and ensure accuracy in their experiments. In this interview, Jean-François also highlights how the company’s offerings have supported researchers throughout the COVID-19 pandemic.

Technology Networks recently had the pleasure of speaking with Abpro’s CEO, Ian Chan, to learn more about the company’s research and development pipeline. Chan discusses in detail the development of ABP-300, a monoclonal antibody that neutralizes SARS-CoV-2 by associating with the virus’s spike protein.

We spoke to Dr Lorna Ewart, Emulate’s executive vice president of science, to learn more about the limitations of traditional inflammatory intestinal disease models, what makes the Colon Intestine-Chip a more relevant model and how it can be used to investigate potential drug targets.

In this interview, Dr Sudeb Dalai, senior medical director at Adaptive Biotechnologies, discusses the role that T-cell analysis may play in the diagnosis and treatment of diseases including SARS-CoV-2.

Here we summarize the webinar that was hosted by Klaus Hochleitner, PhD., which provides an overview of the important factors and considerations for robust lateral flow assay development.

A new body of work published in Science Translational Medicine outlines the preclinical testing of a microRNA-based gene therapy for Huntington's disease – AMT-130 – in minipigs.

In this interview, Technology Networks spoke with Neal Goodwin, PhD, Chief Scientific Officer at Teknova, to learn more about current bioprocessing and bioproduction trends in the cell and gene therapy space. Goodwin also discusses the impact of the COVID-19 pandemic on the biopharmaceutical sector and highlights how the industry has united to contribute to the development of vaccines at this critical time.